EchinocandinsAntifungal drug class
Echinocandins are a class of antifungal medicines rather than a single peptide. They target fungal cell-wall construction and are used in serious infections, especially in patients needing hospital-level care.
Before comparing this entry. This record represents a drug class rather than one product.
What is Echinocandins?
Echinocandins are a class of antifungal medicines that includes caspofungin, micafungin, anidulafungin and rezafungin. They are particularly relevant to invasive Candida infections in hospital care. 1 2
How it works
They inhibit formation of beta-1,3-glucan, a component of fungal cell walls. Susceptibility and access to the infected tissue help determine whether that mechanism is clinically useful.
Effects studied
What does the evidence show?
Clinical trials of individual antifungal medicines
A family with a shared target
Caspofungin, micafungin, anidulafungin and rezafungin belong to this family. They interfere with production of beta-1,3-glucan, an important component of many fungal cell walls. Human cells lack that wall, which makes it a useful target, but does not remove the possibility of adverse effects.
The clinical problem is invasive infection
An invasive Candida infection is very different from a superficial rash or an unspecified claim about “yeast overgrowth”. Species identification, susceptibility and the infected site guide treatment. Not every fungus responds equally, and drug concentrations vary between tissues, so a broad antifungal label is insufficient.
How to read the trial evidence
The retained trials compare individual echinocandins with other antifungal medicines in defined invasive-infection populations. Success depends on clinical and microbiological outcomes, not simply inhibition in a laboratory dish. A result for one medicine, treatment duration and population cannot rank the entire class. 1 2
What remains drug-specific
Infusion reactions, liver-test abnormalities and interactions require attention. The dosing schedule, evidence base and practical advantages differ between individual agents. This is an introduction to the class. Assessing a treatment requires identifying the exact drug and infection; echinocandins are not general wellness treatments.
Safety & status
Infusion reactions, liver effects and interactions vary by medicine. Species identification, infection site and susceptibility are important when selecting treatment.
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Is an echinocandin one particular peptide?
No. It is a medicine class containing several distinct compounds.
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.